Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions.
WHY WE'RE FUNDRAISING WITH THE JIMMY FUND WALK TO FIGHT CANCER
What Is InAdvance?
InAdvance is a Dana-Farber strategic initiative designed to disrupt the historical cancer care model by bringing state-of-the-art early detection and precision intervention to people at higher risk of developing cancer.
InAdvance was launched in 2022 by Dana-Farber President and CEO Laurie Glimcher, MD, with a multi-disciplinary faculty leadership team and disease center champions across Dana-Farber’s early detection clinical programs. This integrated research-clinical model will accelerate understanding of precursor conditions that precede cancer and bring earlier interventions for patients more rapidly.
Through both research and clinical offerings, InAdvance serves people at elevated risk for developing cancer. This includes people with precursor conditions, environmental exposures, cancer survivors at elevated risk of developing secondary cancers, and those with a family history of cancer.
THANK YOU TO OUR TEAM MEMBERS
= Team CaptainTHANK YOU TO OUR TEAM DONORS
